Novo Nordisk (NYSE: NVO) reported Q2 EPS of DKK10.17. Revenue for the quarter came in at DKK133.41 billion.

OUTLOOK

For the 2024 outlook, sales growth is now expected to be 22-28% at CER, and operating profit growth is now expected to be 20-28% at CER. Growth reported in Danish kroner is now expected to be 1 percentage point lower than at CER growth for both sales and operating profit.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.